An allosteric MALT1 inhibitor is a molecular corrector rescuing function in an immunodeficient patient.
Quancard, Jean; Klein, Theo; Fung, Shan-Yu; Renatus, Martin; Hughes, Nicola; Israël, Laura; Priatel, John J; Kang, Sohyeong; Blank, Michael A; Viner, Rosa I; Blank, Jutta; Schlapbach, Achim; Erbel, Paul; Kizhakkedathu, Jayachandran; Villard, Frédéric; Hersperger, René; Turvey, Stuart E; Eder, Joerg; Bornancin, Frédéric; Overall, Christopher M.
Nat Chem Biol
; 15(3): 304-313, 2019 03.
Artigo em Inglês | MEDLINE | ID: mdl-30692685
Successful clinical treatment and functional immunological normalization of human MALT1 deficiency following hematopoietic stem cell transplantation.
Actin polymerisation after FCÎ³R stimulation of human fibroblasts is BCL10 independent.
Ion channels in innate and adaptive immunity.
Genetic errors of the human caspase recruitment domain-B-cell lymphoma 10-mucosa-associated lymphoid tissue lymphoma-translocation gene 1 (CBM) complex: Molecular, immunologic, and clinical heterogeneity.
Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling.
Dual proteolytic pathways govern glycolysis and immune competence.
The CARD11-BCL10-MALT1 (CBM) signalosome complex: Stepping into the limelight of human primary immunodeficiency.
Malt1-induced cleavage of regnase-1 in CD4(+) helper T cells regulates immune activation.
The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency.